Clinical trials: Metastatic Colorectal Cancer (MCRC)
Colorectal Neoplasms
A Multicenter, Clinical Study of FOLFOXIRI With Bevacizumab As First-line Therapy in Patients With mCRC
The purpose of this study to assess efficacy and tolerability of combination therapy FOLFOXIRI with Bevacizumab (BV) as a first-line therapy in patients with metastatic colorectal cancer.
- Trial name
- QUATTRO (NCT02246049)
- Testing
- Bevacizumab, 5-fluorouracil, Irinotecan hydrochloride
- Where
- Japan
- Volunteers
- 69 people, healthy volunteers welcome
- Sponsor
- EPS Corporation
Metastatic Colorectal Cancer
MEN1611 With Cetuximab in Metastatic Colorectal Cancer (C-PRECISE-01)
Open-label, dose-confirmation and cohort expansion, multicenter, Phase Ib/II study to assess the anti-tumor activity and safety of MEN1611 in combination with cetuximab for the treatment of participants with phosphatidylinositol…
- Trial name
- C-PRECISE-01 (NCT04495621)
- Testing
- MEN1611, Cetuximab
- Where
- 28 sites in United States, France and 5 more
- Volunteers
- 29 people
- Sponsor
- Menarini Group
Microsatellite Stable Metastatic Colorectal Cancer, Metastatic Colorectal Cancer
Immunotherapies in Combination With Stereotactic Body Radiation Radiotherapy in Microsatellite Stable (MSS) Metastatic Colorectal Cancer (mCRC)
Background: Metastatic colorectal cancer (mCRC) is cancer that has spread beyond the colon and rectum. Most people with mCRC die within 5 years. New immune-based treatments are making progress with some types of colon cancer.
- Conditions
- Microsatellite Stable Metastatic Colorectal Cancer, Metastatic Colorectal Cancer, Colorectal Cancer
- Trial name
- NCT06603818
- Testing
- Tiragolumab, Atezolizumab, Stereotactic Body Radiation Therapy (SBRT)
- Where
- United States
- Sponsor
- National Cancer Institute (NCI)
Metastatic Colorectal Cancer
A Retrospective Review of Liver Resection Rate in Metastatic Colorectal Cancer Patients Following Downsizing Treatment With Chemotherapy Plus Cetuximab in Normal UK National Health Service Clinical Practice
This study is a multi-centre retrospective observational research study which will be conducted in UK centres with specialised liver surgical services.
- Trial name
- RESECT (NCT01460745)
- Where
- 5 sites in United Kingdom
- Volunteers
- 60 people
- Sponsor
- Merck KGaA, Darmstadt, Germany
Colorectal Cancer
Metronomic Versus Conventional Chemotherapy in as Maintenance Treatment in mCRC
The optimum regimen of maintenance treatment after first-line chemotherapy in patients with metastatic colorectal cancer (mCRC) is unknown.
- Trial name
- NCT02893540
- Testing
- Capecitabine
- Where
- China
- Volunteers
- 250 people
- Sponsor
- Ruijin Hospital
Metastatic Colorectal Cancer, BRAF V600 Mutation
A Study on Treatment for Patients With BRAFV600E Mutant Metastatic Colorectal Cancer (mCRC)
Previous studies have shown that BRAFV600E mutant mCRC patients have a shorter survival time than BRAF wild type mCRC patients. For Chinese patients, however, it remains unclear about the BRAF gene mutation rate, diagnosis…
- Trial name
- NCT06749015
- Testing
- Non interventional study
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Fudan University
Colorectal Cancer with Hepatic Metastases
TATE and KN046 in MCRC
A single-arm, multicenter, Phase IIA study of Intra-arterial Administration of Tirapazamine followed by Transarterial Embolization (TATE) and KN046 (recombinant humanized anti-PD-L1/CTLA-4 bispecific single-domain antibody Fc…
- Trial name
- NCT06834399
- Testing
- KN046 （PD-L1/CTLA4 BsAb）, TATE：Intra-arterial Administration of Tirapazamine followed by Transarterial Embolization
- Where
- China
- Volunteers
- 42 people
- Sponsor
- Zhejiang Raygene Pharmaceuticals Co., Ltd
Metastatic Colorectal Cancer, RAS Mutation
Centralized Tumour Board and Secondary Intervention Rate in mCRC
This is a randomised, multicentre observational study in patients suffering from RAS mutant mCRC with primarily unresectable metastases, who are planned to be treated with FOLFOXIRI and bevacizumab or who have already received ≤…
- Conditions
- Metastatic Colorectal Cancer, RAS Mutation, Multidisciplinary Communication, Secondary Intervention
- Trial name
- NCT04852250
- Testing
- Virtual centralized multidisciplinary tumour board
- Volunteers
- 130 people
- Sponsor
- Ludwig-Maximilians - University of Munich
Metastatic Colorectal Cancer
To Determine the MTD and to Evaluate the Safety, Efficacy and PK Profiles of TSB-9-W1 in Pre-treated Patients With mCRC.
TSB-9-W1, prepared by Taiwan Sunpan Biotechnology Co., Ltd. (TSB) is a botanical drug and applied patent in the United States (US patent No. 7,138,428 B2), Japan (Patent No. 5441947) and Taiwan (Patent No. I432191 and I282280).
- Trial name
- TSB-9-W1 (NCT02249650)
- Testing
- TSB-9-W1
- Where
- Taiwan
- Volunteers
- 21 people
- Sponsor
- Taiwan Sunpan Biotechnology Development Co., Ltd.
Metastatic Colorectal Cancer
Irinotecan Plus Anlotinib or Further in Combination With Penpulimab for Second-line Treatment of mCRC
This is an exploratory, non-controlled, multi-cohort, phase II small-sample clinical study designed to evaluate the clinical benefit of second-line treatment with anlotinib plus irinotecan or further in combination with a PD-1…
- Trial name
- NCT05229003
- Testing
- Anlotinib, Penpulimab, Irinotecan
- Where
- China
- Volunteers
- 44 people
- Sponsor
- Fudan University
Colon Adenocarcinoma, Rectal Adenocarcinoma
Lower or Standard Dose Regorafenib in Treating Patients With Refractory Metastatic Colorectal Cancer
This randomized phase II trial studies how well lower-dose compared to standard dose regorafenib works in treating patients with colorectal cancer that has spread from the primary site (place where it started) to other places in…
- Conditions
- Colon Adenocarcinoma, Rectal Adenocarcinoma, Stage III Colorectal Cancer AJCC v7, Stage IIIA Colorectal Cancer AJCC v7
- Trial name
- NCT02368886
- Testing
- Clobetasol Propionate, Pharmacological Study, Quality-of-Life Assessment
- Where
- 22 sites in United States
- Volunteers
- 123 people
- Sponsor
- Academic and Community Cancer Research United
Metastasis Colorectal Cancer, Colon Cancer
Study of Fruquintinib Combined With Tegafur Gimeracil Oteracil in Patients With Metastatic Colorectal Cancer
This is an Open, Single-arm, Multicenter, Prospective Phase II Study of Fuquinitinib Combined With Tegafur Gimeracil Oteracil in the Third-line Treatment of Patients With Advanced Metastatic CRC
- Conditions
- Metastasis Colorectal Cancer, Colon Cancer, Rectal Cancer
- Trial name
- NCT06255379
- Testing
- Fuquinitinib+Tegafur Gimeracil Oteracil
- Where
- China
- Volunteers
- 52 people
- Sponsor
- Guangzhou University of Traditional Chinese Medicine
Colon Cancer
PhII Trial Panitumumab, Nivolumab, Ipilimumab in Kras/Nras/BRAF Wild-type MSS Refractory mCRC
To investigate the combination of nivolumab and ipilimumab with panitumumab in subjects with unresectable, refractory, KRAS/NRAS/BRAF wild-type, microsatellite stable (MSS) metastatic colorectal cancer.
- Trial name
- NCT03442569
- Testing
- Panitumumab, Nivolumab, Ipilimumab
- Where
- 5 sites in United States
- Volunteers
- 56 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Cetuximab-induced Papulopustular (Acneiform) Rash Who Have, Metastatic Colorectal Cancer or Head and Neck Squamous Cell Carcinoma
Study of Prophylactic Topical Dapsone 5% Gel Versus Moisturizer for Cetuximab-induced Papulopustular (Acneiform) Rash in Patients With mCRC or HNSCC Without Previous or Concurrent RT
The purpose of this study is to see if the investigators can prevent or reduce the severity of the Cetuximab-related acne rash. Two different topical agents will be applied to the skin.
- Trial name
- NCT01931150
- Testing
- Topical Dapsone 5% Gel, Moisturizer, oral antibiotics
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Colo-rectal Cancer, Third-line and Beyond Therapy
Low-dose Trifluridine/Tipiracil With Bevacizumab in mCRC
This is a phase II, single-center, prospective trial aimed to investigate the efficacy and safety of a modified regimen of trifluridine/tipiracil plus bevacizumab in refractory metastatic colorectal cancer.
- Conditions
- Colo-rectal Cancer, Third-line and Beyond Therapy, TAS 102, Bevacizumab
- Trial name
- NCT07085169
- Testing
- Trifluridine/tipiracil (TAS-102) plus bevacizumab
- Where
- 2 sites in China
- Volunteers
- 50 people
- Sponsor
- Ruijin Hospital
Colon Cancer
Safety Study of Recombinant NAPc2 to Prevent Tumor Progression and Metastases in Metastatic Colon Cancer
This is a multicenter, two-stage trial with the goal of evaluating up to 100 subjects. This trial will be performed to initiate identification of a safe and effective dose of twice-weekly, subcutaneous rNAPc2 for the second-line…
- Trial name
- NCT00443573
- Testing
- recombinant nematode anticoagulant protein c2 (rNAPc2)
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- ARCA Biopharma, Inc.
Metastatic Colorectal Carcinoma (mCRC), Colorectal Cancer (CRC)
Safety and Efficacy of Tegavivint in Patients With Metastatic Colorectal Carcinoma
This trial will evaluate the safety, tolerability, and preliminary efficacy of tegavivint as monotherapy (single) and in combination with standard therapies in patients with metastatic colorectal carcinoma (mCRC).
- Conditions
- Metastatic Colorectal Carcinoma (mCRC), Colorectal Cancer (CRC), Adenomatous Polyposis Coli (APC) Gene Mutation, Catenin Beta-1 (CTNNB1) Gene Mutation
- Trial name
- NCT07463599
- Testing
- Tegavivint
- Where
- United States
- Volunteers
- 126 people
- Sponsor
- HonorHealth Research Institute
Metastatic Colorectal Cancer (mCRC), Colorectal Neoplasms
Efficacy And Safety Of Hydroxychloroquine Combined With Methotrexate, Capecitabine And Bevacizumab Vs. Regorafenib In Participants With Refractory Metastatic Colorectal Cancer With Mutations In RAS Genes
This study will evaluate efficacy and safety of hydroxychloroquine combined with methotrexate, capecitabine and bevacizumab versus regorafenib in participants with refractory metastatic colorectal cancer with mutations in KRAS or…
- Trial name
- x-МАР (NCT06949982)
- Testing
- experimental group x-MAP, Regorafenib (BAY 73-4506)
- Where
- Russia
- Volunteers
- 60 people
- Sponsor
- Sergey Orlov, MD
Advanced Metastatic Colorectal Cancer
SALIRI Based Regimen as First-line Treatment for Advanced Metastatic Colorectal Cancer
The objective is to investigate the efficacy and safety of raltitrexed combined with Irinotecan (SALIRI) based regimen as first-line treatment for advanced metastatic colorectal cancer(mCRC).
- Trial name
- NCT05160896
- Testing
- Raltitrexed, Irinotecan, Bevacizumab
- Where
- China
- Volunteers
- 90 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Metastatic Colorectal Cancer
A Study of Fruquintinib in Adults With Metastatic Colorectal Cancer in Poland
Metastatic colorectal cancer or mCRC is a cancer that starts in the parts of the large intestine (the colon or rectum) and has already spread to other parts of the body.
- Trial name
- NCT07623174
- Testing
- No intervention
- Where
- 10 sites in Poland
- Volunteers
- 110 people
- Sponsor
- Takeda